Landos Biopharma Provides Business Update and Reports Fourth Quarter and Full Year 2023 Results

Top-line Results from the NEXUS Phase 2 Clinical Trial of NX-13 for Ulcerative Colitis Planned for Q4 2024

Sufficient Cash to Fund Planned Operations into mid-2025